Rocket Pharmaceuticals, Inc. Common Stock
RCKT
RCKT: Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
moreShow RCKT Financials
Recent trades of RCKT by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by RCKT's directors and management
Government lobbying spending instances
-
$10,000 Jul 19, 2022 Issue: Health Issues
-
$10,000 Apr 20, 2022 Issue: Health Issues
-
$10,000 Jan 20, 2022 Issue: Health Issues
-
$10,000 Nov 19, 2021 Issue: Health Issues
-
$10,000 Jul 19, 2021 Issue: Health Issues
-
$30,000 Oct 20, 2020 Issue: Immigration
-
$20,000 Jul 17, 2020 Issue: Immigration
-
$20,000 Apr 13, 2020 Issue: Immigration
-
$40,000 Jan 15, 2020 Issue: Immigration
New patents grants
-
Patent Title: Gene therapy vectors for treatment of danon disease Jul. 07, 2020
Federal grants, loans, and purchases
Followers on RCKT's company Twitter account
Number of mentions of RCKT in WallStreetBets Daily Discussion
Recent insights relating to RCKT
Recent picks made for RCKT stock on CNBC
ETFs with the largest estimated holdings in RCKT
Flights by private jets registered to RCKT